[Pharmacological thromboprophylaxis in gynecology and obstetrics].

[heparin-induced thrombocytopenia]

Venous thromboembolism (VTE ) is associated with high morbidity and mortality . Therefore , effective methods for safe thromboprophylaxis remain an ongoing challenge in daily clinical practice . This is especially true for pregnant women and patients with gynaecological malignancies . Low -molecular weight heparins continue to be agents of choice for pharmacological thromboprophylaxis postoperatively , in pregnant patients at risk , and during the puerperium . However , these drugs can cause bleeds or heparin-induced thrombocytopenia (type II ). Based on recent revisions of corresponding guidelines , this article provides an overview of the current state of pharmacological thromboprophylaxis and discusses prevailing problems and unresolved issues .